GARLIT: Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly
Study Details
Study Description
Brief Summary
Objective: To determine in real life the efficacy, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chronic (CM) migraine.
Design: This prospective observational cohort study was conducted between November 2019 and January 2021.
Participants: Consecutive adult HFEM and CM patients clinically prescribed galcanezumab were enrolled.
Setting: Multicenter study in 13 Italian headache centers.
Exposure: Galcanezumab subcutaneous injection 120 mg monthly with the first loading dose of 240 mg.
Main Outcome(s) and Measure(s): The primary end-point was the change in monthly migraine days (MMDs) in HFEM patients and monthly headache days (MHDs) in CM ones after six months of therapy (V6) compared to baseline. Secondary end-points included variation in Numerical Rating Scale (NRS), monthly painkiller intake (MPI), HIT-6, and MIDAS scores. We assessed 50%, 75%, and 100% responder rates (RR), the conversion rate from CM to episodic migraine (EM), and the Medication Overuse condition to the non-overuser.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
GARLIT is an independent, multicenter, prospective, cohort, real-life study. All consecutive patients aged 18 or older with a diagnosis of HFEM (8-14 migraine days per month) or CM (1.3 ICHD-3), who had failed at least three migraine preventive treatments and not previously involved in any CGRP mAbs trial, are considered for enrolment. Patients are assessed at baseline by a headache expert neurologist with a face-to-face interview using a semi-structured questionnaire addressing socio-demographic factors, clinical migraine features, previous and current acute and preventive migraine treatments, comorbidities and concomitant medications. Headache-related dopaminergic and autonomic symptoms, temporal artery turgidity/hyperpulsatility, and allodynia during or between attacks are also investigated. Patients are also requested to rate the overall efficacy of triptans in most attacks as none/poor (0) or fair/excellent (1).
Enrolled patients will carefully fill in a headache diary during a run-in month period (baseline) and the entire duration of the study, to report monthly migraine days (MMDs) for HFEM patients, all monthly headache days (MHDs) of at least moderate intensity for CM subjects, and monthly painkillers intake (MPI). Patients were also asked to rate pain severity (using the 0-10 Numerical Rating Scale, NRS) of the worst painful attack and fill in migraine disability questionnaires (Headache Impact Test, HIT-623, monthly, and the MIgraine Disability Assessing Scale24, MIDAS, quarterly).
Patients will be treated with galcanezumab subcutaneous injection with the first loading dose of 240mg and then every month with 120mg as recommended, according to real life clinical indication (www.europa.ema.eu).
The above-reported variables and any adverse event (AE) are recorded at baseline and monthly at every in-office visits. Telephone/email contacts are allowed when in-office visits are not possible. All AEs are reported to Eudravigilance and classified as gastrointestinal (e.g. nausea, constipation), cutaneous (e.g. injection-site reactions: rash/erythema, pruritus, urticaria, oedema/induration), arthralgia, Raynaud phenomenon, dizziness and other (<1% of patients: i.e. somnolence, alopecia, anxiety).
Patients will provide written informed consent.
Study Design
Outcome Measures
Primary Outcome Measures
- e change in monthly migraine days (MMDs) on galcanezumab therapy compared to baseline [baseline, monthly and through therapy cycle completion which is an average of 1 year. and after three months after therapy withdrawal.]
MMDs defined as monthly migraine days collected by headache diary
Secondary Outcome Measures
- variation in Numerical Rating Scale (NRS), monthly painkiller intake (MPI) during galcanezumab therapy compared to baseline [baseline, monthly and through therapy cycle completion, which is an average of 1 year, and after three months after therapy withdrawal.]
NRS= 0-to-10 pain intensity of the worst migraine attacks perceived in the previous month, MPI= the number of painkiller taken in the previous month.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
the clinical indication for Galcanezumab as a preventive treatment for Migraine according to European Medicines Agency
-
age18 years or older
-
8 or more mean Monthly Migraine Headache days in the last three months
Exclusion Criteria:
- previous exposure to any monoclonal antibodies inhibiting CGRP pathway, including clinical trials
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Campus Bio Medico University Hospital | Rome | RM | Italy | 00122 |
Sponsors and Collaborators
- Campus Bio-Medico University
Investigators
- Principal Investigator: Fabrizio Vernieri, MD, Campus Bio-Medico University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GARLIT
- IRB Number